Original research article| Volume 76, ISSUE 1, P66-70, July 2007

Increasing access to safe abortion services in rural India: experiences with medical abortion in a primary health center



      To increase access to safe abortion in rural India, the feasibility and acceptability of mifepristone���misoprostol abortion was assessed in a typical government run primary health center (PHC) in Nagpur district, Maharashtra State, that does not offer surgical abortion services and must refer off-site for emergency and backup services.

      Materials and Methods

      Consenting pregnant women (n=149) with ���56 days amenorrhea seeking terminations received 200 mg mifepristone, and returned 48 h later for 400-��g sublingual misoprostol and 12 days later for abortion confirmation. Surgical backup was conducted at a nearby community health center (CHC).


      Nearly all women (98.6%) with known outcomes had successful medical abortions, and those who did not (1.4%) were successfully referred to the CHC for surgical backup. Women reported the method's ease and simplicity as the best features.


      Medical abortion provision is feasible and acceptable in an Indian rural PHC that does not offer surgical abortion services. This study suggests that introduction of medical abortion at lower levels of the health-care system could increase access to safe abortion in rural India.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Contraception
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Government of India
        Survey of causes of maternal deaths (rural): annual report.
        Office of the Registrar General of India, New Delhi1990
        • Khan M.E.
        • Barge S.
        • Kumar N.
        • Almroth S.
        Abortion in India: current situation and future challenges.
        in: Pachauri S. Implementing a reproductive health agenda in India: the beginning. Population Council, New Delhi1999: 507-529
        • Coyaji K.
        • Elul B.
        • Krishna U.
        • et al.
        Mifepristone abortion outside the urban research hospital setting in India.
        Lancet. 2001; 357: 120-121
        • Coyaji K.
        • Elul B.
        • Krishna U.
        • Otiv S.
        • et al.
        Mifepristone���misoprostol abortion: a trial in rural and urban Maharashtra, India.
        Contraception. 2002; 66: 33-40
        • Takkar D.
        • Aggarwal N.
        • Seghal R.
        • Buckshee K.
        Early abortion by mifepristone (RU 486) followed by vaginal gel (metenprost) versus oral (misoprostol) prostaglandin.
        Advances in Contraception. 1999; 15: 163-173
        • Winikoff B.
        • Sivin I.
        • Coyaji K.J.
        • et al.
        Safety, efficacy, and acceptability of medical abortion in China, Cuba, and India: a comparative trial of mifepristone���misoprostol versus surgical abortion.
        Am J Obstet Gynecol. 1997; 176: 431-437
      1. Winikoff B, Sivin I, Coyaji KJ. et al. The acceptability of medical abortion in China, Cuba and India. Int Fam Plann Perspect 1997;23:73���8, 89.

        • World Health Organisation Task Force on Post-Ovulatory Methods of Fertility Regulation
        Termination of pregnancy with reduced doses of mifepristone.
        BMJ. 1993; 307: 532-537
        • World Health Organisation Task Force on Post-Ovulatory Methods of Fertility Regulation
        Comparison of two doses of mifepristone in combination with misoprostol for early medical abortion: a randomised trial.
        Br J Obstet Gynaecol. 2000; 107: 524-530
        • Elul B.
        • Hajri S.
        • Ngoc N.N.
        • et al.
        Can women in less-developed countries use a simplified medical abortion regimen?.
        Lancet. 2001; 357: 1402-1405
        • World Health Organisation
        Safe abortion: technical and policy guidance for health systems.
        World Health Organisation, Geneva2003
        • Tang O.S.
        • Schwer H.
        • Seyberth H.W.
        • Sharon W.H.
        • Ho P.C.
        Pharmacokinetics of different routes of administration of misoprostol.
        Hum Reprod. 2002; 17: 332-336
        • Winikoff B.
        • Ellertson C.
        • Clark S.
        Analysis of failure in medical abortion.
        Contraception. 1996; 54: 323-327
        • Elul B.
        • Ellertson C.
        • Winikoff B.
        • Coyaji K.
        Side effects of mifepristone���misoprostol abortion versus surgical abortion.
        Contraception. 1999; 59: 107-114
        • Tang O.S.
        • Chang C.C.W.
        • Ng E.H.Y.
        • Lee S.W.H.
        • Ho P.C.
        A prospective, randomized, placebo-controlled trial on the use of mifepristone with sublingual or vaginal misoprostol for medical abortions of less than 9 weeks gestation.
        Hum Reprod. 2003; 11: 2315-2318